Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTL0812 with chemotherapy in advanced endometrial cancer and squamous NSCLC
NCT03366480Phase 2Completed
- Sponsor
- AbilityPharma
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrilatazar in endometrial cancer (EC), squamous cell carcinoma of the lung (SCCL), sponsored by AbilityPharma. Started Dec 2016; status: completed.
02
Drugs
ibrilatazar
03
Conditions
endometrial cancer (EC)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03366480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366480.